AlphaBioComis the scientific communication

powerhouse that delivers your most precious assets

with precision, integrity, and passion

Confidential – Not for Distribution

• Global capability• US and UK facilities• Strength in experience• Exclusively in-house team

All have at least 4 years experience

All have PhDs Full service

• We create, refine and communicate value for your assets

Confidential – Not for Distribution

Inside AlphaBioCom

• Autoimmune Disease• Cardiovascular• Dermatology• Endocrinology• Gastroenterology• Genetics• Gynecology• Immunology• Infectious Disease• Metabolic

• Neuroscience/ Neuropsychology

• Obstetrics/Gynecology• Oncology• Pain Management• Pulmonology/

Respiratory Disease• Renal and Urology• Rheumatology• Virology

Confidential – Not for Distribution

Therapeutic Expertise

Experience Across the Product Life Cycle

• CERVISTA• CERVARIX• ULORIC• LA HPV TEST• MENHIBRIX• MONOPREP• RESLIZUMAB• IXIARO

• ORALGAM• ACHN-490• MENHIBRIX• Nano Assets

• ADIANA• NOVASURE• CERVISTA• CERVARIX• ULORIC• HAVRIX• PEDIARIX• TWINRIX• CERVISTA• OPTAFLU• FLUAD• AVODART

• ORALGAM • ACHN-490• ACHN-750• ACHN ESA• Nano assets

• AVODART• ADIANA• BACTROBAN• NOVASURE• CERVISTA• CERVARIX• FLUVIRIN• PEDIARIX• IXIARO• TWINRIX• HAVRIX• NAPROXEN• DICLOFENAC• INDOCIN • ULORIC• RYTHMOL SR• ALTABAX• LOVAZA

Phase I Phase II Phase IVProduct LaunchPhase III

Confidential – Not for Distribution

Experience into our 7th Year

Confidential – Not for Distribution

Scientific communication planning

Scientific communication development and execution

Thought Leader identification and engagement

Scientific Communication Service

• Systematic approach to ensuring that you reach your audience with the right data, information at the right time with the right frequency to create a change in understanding and/or awareness– AlphaBioCom

Scientific communication planning?

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Planning cycle

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

• Visualize, characterize and state the shift that you aim to create

Objectives

Awareness Beliefs Knowledge

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

• Intelligent Approach– Understanding and managing Issues

and Objectives• Driven by advanced SWOT analysis• Affirmative issues to assert advantages• Barriers and disadvantages to weigh

and balance– Route to success• Clear defined roadmap to achieve goals

Strategy

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Audience

How do we define and describe

them?

How do we communicate with them?

How will we know we have

communicated effectively?

Who do we need to communicate

with?

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Scientific Message

Tier1

Tier 2

Tier 3

• Core communication points

• Primary scientific evidence

• Evidence based medicine

• Health Economics and Outcomes Research

• Benefits and attributes from literature.

• Reviews and supporting clinical trials

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Journals

Impact

Specialty

Time

Acceptance

Congresses

Time

Audience

Acceptance

Interactive tools

On-Line Journals

Web based interactive

publications

Interruptive mediaCompany Apps

Scientific Channel Considerations

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Review and refine

Execute deliverables in line with plan framework

Populate content and finalize plan

Research authors

Identify plan framework

Delve into science

Situation analysis

Execution

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

• Strict adherence to policies• Clear defined training and QA procedures• Proven development processes

– Abstracts– Posters– Oral presentations– Manuscripts

• Data Management and Integrity – Communications trail– Audited processes

• Precise project reporting

• How do you manage these processes?

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Precision Processes

What•results versus objectives•milestones versus plans

When•cyclical

•before •during•after

How•set and measure key

performance indicators

Planning & Measurement

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Confidential – Not for Distribution

ID Task NameDuratio

nStart Finish Jan Feb

March

April May June July

1 Program106 days

Wed Jan 28, ‘09 Wed Jan 24, ‘09

2 Research 10 days Wed Jan 28, ‘09 Tues Feb 10, ’09

3Call w/ author and create outline

5 daysWed Feb 11, ‘09

Tues Feb 17, ’09

4 Expanded outline to client 15 daysWed Feb 18, ’09

Tues Mar 10, ’09

5 Client comments on outline 10 daysWed Mar 11, ’09

Tues Mar 24, ’09

6Expanded outline to authors

10 daysWed Mar 25, ’09

Tues April 7, ’09

7 Authors comments to ABC 10 daysWed April 8, ’09

Tues April 21, ’09

8Client comments on 1st draft to ABC

5 daysWed April 22, ’09

Tues April 28, ’09

9 Draft 1 to author 10 daysWed April 29, ’09

Tues May 12, ’09

10 Author review of Draft 1 10 daysWed May 13, ’09

Tues May 26, ’09

11Draft 2 to authors and Client

5 daysWed May 27, ’09

Tues Jun 2, ‘09

12 All comments due to ABC 5 days Wed Jun 3, ’09 Tues Jun 9, ‘09

13Final draft to authors and Client

5 days Wed Jun 10, ’09 Tues Jun 16, ‘09

14All comments and final approval due

5 days Wed Jun 17, ’09 Tues Jun 23, ‘09

15 Submission 1 day Wed Jun 24, ‘09 Wed Jun 24, ‘09

Writer

Writer

Writer

Writer

Writer

Writer

Writer

Author/Writer

Author

Author

Client/Author

Client/Author

Client

Client

Planning & Measurement

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

Project #Project Name

StartEstimated

FinishStatu

sVariance Comments

ADV01 Case Study 12/27/09 3/13/10 On Track Waiting for data

ADV02Abstract

PKPD11/23/09 1/10/10 +10 days

Awaiting data from Clinical

ADV03 Symposia 12/3/09 5/9/10 +5 daysFaculty

presentation catch up plan in place

ADV04Primary

Manuscript12/6/09 6/20/10 On Track

On target for first draft

ADV05 Ad Board 3/16/10 10/23/10 On TrackCreating advisor

list

On TrackVariance +/- 5 days

CautionVariance 5-10 days off

Off TrackVariance + 10 days

Confidential – Not for Distribution

Planning & Measurement

Strategy

Audience

Messages

Channels

Execution

Measurement

Objectives

AlphaBioCom broadest publication experience• Published in over 100 journals• Across 20 different

therapeutic categories• Spanning US, Eu and

International journals• Working with more 500

authors • Located in 10 different

countries

• Yet we demand that every single paper receives the same precision, integrity and passion as our first!

Publication Powerhouse

Our Clients

Confidential – Not for Distribution

Clients ….Partners

•19 plansScientific Communication Plans

•>250 scientific manuscripts

•>100 congress submissions (abstracts, posters)

•>200 scientific presentations

Scientific Communication

Deliverables

•70 advisory boards

•25 TL education programs

TL/KOL

Precision, Integrity and Passion in our 7th year

•100% approved and implemented

Scientific Communication Plans

•>90% acceptance first journal submitted

•100% all journal submissions

•>98% acceptance first congress

Scientific Communication

Deliverables

Performance Indicators: Precision, Integrity and Passion in numbers.

• Zero manuscripts rejected due to poor quality writing

• Never cited for inaccuracies or data management error by any client

• Never cited for a process compliance issue by any client

• Never had to withdraw any deliverable due to error

• Never failed a client audit• Zero citations in any newspaper

• Evidence our processes are robust and work

Power in the Negative

Contact Information

Stephen DouthwaitePresident and Chief Strategist

2 Radnor Corporate Center, Suite 200100 Matsonford Road

Radnor, PA 19087(610) 225-0400

stephend@alphabiocom.com

Confidential – Not for Distribution